Clin Surg | Volume 7, Issue 1 | Research Article | Open Access

A New Tumor Therapeutic Vaccine: A Real-World Survey on Treatment of 68 Patients with Advanced Cancer

Kecheng Xu1*, Wei Qian1, Zhongbao Pan1, Xiaofeng Kong2, Yongyong Lu3, Tianyu Lu2 and Dinggang Li4*

1Department of Internal Medicine of Oncology, Fuda Cancer Hospital, Jina University, China
2Cancer Rehabilitation Center, Fuda Cancer Hospital, Jina University, China
3Molecular Biology Institute, Peking University, China
4Department of Surgery Oncology, Beijing Lu Daopei Hematology Hospital, China

*Correspondance to: Kecheng Xu 

Fulltext PDF

Abstract

Tumor Therapeutic Vaccine (TTV) is a complex composed of a variety of bacteria or their toxin vaccines plus adjuvants. Bacterial vaccines include pertussis, typhoid/paratyphoid A/B, and Staphylococcus aureus, bacterial toxin vaccines include diphtheria toxin and tetanus toxin, and adjuvants include dextran and others. A total of 68 patients with advanced solid cancer, who received only TTV injections after failing conventional treatments, underwent a real-world survey. Results: The time of receiving TTV injection treatment was 3 to 96 months, with a median of 24 months; tumor Complete Response (CR) was seen in 44.1% of cases, Partial Response (PR) 36.7%, Stable (SD) 19.1%; since TTV treatment, the overall survival period of patients is 8 to 204 months, with a median of 48 months. At the last follow-up, there are 48.5% of survivors. This survey shows that this simple and safe treatment method can effectively promote tumor regression or stabilize it, and prolong the survival of patients. In some cases, it can cause a miraculous reversal of the disease. For advanced cancer, TTV can be regarded as a promising alternative treatment.

Keywords:

Immunotherapy; Bacterial vaccine; Tumor therapy vaccine; Coley toxin

Citation:

Xu K, Qian W, Pan Z, Kong X, Lu Y, Lu T, et al. A New Tumor Therapeutic Vaccine: A Real-World Survey on Treatment of 68 Patients with Advanced Cancer. Clin Surg. 2022; 7: 3432..

Subscribe to Our Newsletter